The Company was founded by Samih Darwazah in 1978 in Amman in Jordan. In August 1996 it became the first Arab company to export pharmaceutical products to the United States. It was first listed on the London Stock Exchange in 2005. Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005 and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006. In 2007 the Company went on to buy APM in Jordan, Alkan Pharma in Egypt,APM and Al Jazeera Pharma in Saudi Arabia Thymoorgan in Germany and Ribosepharm in Germany. It also acquired Multi-Source Injectables in the USA in October 2010. In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).
What makes a great place to work? Our colleagues from around the world wanted to share a few thoughts about why they love working at Hikma. #OwnYourCareer #HikmaCares
published: 08 Jun 2021
Hikma Intern Office Tour 2021| UK | US|
Some of our interns from the UK and US give you a tour of some of our offices. #HikmaInterns #HikmaCollaborates #Progress&Belonging #HikmaCares
published: 30 Sep 2022
Hikma Pharmaceuticals - Hot or Not
Hikma Pharmaceuticals (LSE-London:HIK) was founded in Jordan and is now mostly a multinational generic pharmaceutical manufacturer. It has a market cap of GBP 4.1 billion, a PE of 33.5 and a dividend yield of 1.51 per cent. Guest Jean Pierre Verster from Fairtree Capital and resident expert Paul Theron from Vestact decide whether Hikma Pharmaceuticals is hot or not.
published: 19 May 2017
Overview of Hikma injectables business
Introduction to our injectables business.
published: 08 Jun 2021
Hikma Medicine Donation US programme 2023
published: 05 Feb 2024
Riad Mishlawi, CEO at Hikma
We are thrilled to share a video message from our new CEO, Riad Mishlawi.
Together we look forward to working under his leadership
to build a bright and promising future for Hikma.
published: 01 Sep 2023
Our Columbus Ohio Facility Jan 2024 1
published: 31 Jan 2024
Hikma 503B
Corporate video production, animation & virtual event production company based in New Jersey. View our full portfolio at https://perlowproductions.com/portfolio/ and contact us at (856) 669-1669 or [email protected] .
Hikma, Better Health, 503B, Health, Hospital Administration
published: 23 Feb 2022
Hikma US Jan 2024 30Sec
published: 06 Feb 2024
Hikma Pharmaceuticals in the eyes of Dr. Samih Darwazah
Arabic interview with the company's founder about his journey in establishing Hikma Pharmaceuticals
What makes a great place to work? Our colleagues from around the world wanted to share a few thoughts about why they love working at Hikma. #OwnYourCareer #Hikm...
What makes a great place to work? Our colleagues from around the world wanted to share a few thoughts about why they love working at Hikma. #OwnYourCareer #HikmaCares
What makes a great place to work? Our colleagues from around the world wanted to share a few thoughts about why they love working at Hikma. #OwnYourCareer #HikmaCares
Hikma Pharmaceuticals (LSE-London:HIK) was founded in Jordan and is now mostly a multinational generic pharmaceutical manufacturer. It has a market cap of GBP ...
Hikma Pharmaceuticals (LSE-London:HIK) was founded in Jordan and is now mostly a multinational generic pharmaceutical manufacturer. It has a market cap of GBP 4.1 billion, a PE of 33.5 and a dividend yield of 1.51 per cent. Guest Jean Pierre Verster from Fairtree Capital and resident expert Paul Theron from Vestact decide whether Hikma Pharmaceuticals is hot or not.
Hikma Pharmaceuticals (LSE-London:HIK) was founded in Jordan and is now mostly a multinational generic pharmaceutical manufacturer. It has a market cap of GBP 4.1 billion, a PE of 33.5 and a dividend yield of 1.51 per cent. Guest Jean Pierre Verster from Fairtree Capital and resident expert Paul Theron from Vestact decide whether Hikma Pharmaceuticals is hot or not.
We are thrilled to share a video message from our new CEO, Riad Mishlawi.
Together we look forward to working under his leadership
to build a bright and promisi...
We are thrilled to share a video message from our new CEO, Riad Mishlawi.
Together we look forward to working under his leadership
to build a bright and promising future for Hikma.
We are thrilled to share a video message from our new CEO, Riad Mishlawi.
Together we look forward to working under his leadership
to build a bright and promising future for Hikma.
Corporate video production, animation & virtual event production company based in New Jersey. View our full portfolio at https://perlowproductions.com/portfolio...
Corporate video production, animation & virtual event production company based in New Jersey. View our full portfolio at https://perlowproductions.com/portfolio/ and contact us at (856) 669-1669 or [email protected] .
Hikma, Better Health, 503B, Health, Hospital Administration
Corporate video production, animation & virtual event production company based in New Jersey. View our full portfolio at https://perlowproductions.com/portfolio/ and contact us at (856) 669-1669 or [email protected] .
Hikma, Better Health, 503B, Health, Hospital Administration
What makes a great place to work? Our colleagues from around the world wanted to share a few thoughts about why they love working at Hikma. #OwnYourCareer #HikmaCares
Hikma Pharmaceuticals (LSE-London:HIK) was founded in Jordan and is now mostly a multinational generic pharmaceutical manufacturer. It has a market cap of GBP 4.1 billion, a PE of 33.5 and a dividend yield of 1.51 per cent. Guest Jean Pierre Verster from Fairtree Capital and resident expert Paul Theron from Vestact decide whether Hikma Pharmaceuticals is hot or not.
We are thrilled to share a video message from our new CEO, Riad Mishlawi.
Together we look forward to working under his leadership
to build a bright and promising future for Hikma.
Corporate video production, animation & virtual event production company based in New Jersey. View our full portfolio at https://perlowproductions.com/portfolio/ and contact us at (856) 669-1669 or [email protected] .
Hikma, Better Health, 503B, Health, Hospital Administration
The Company was founded by Samih Darwazah in 1978 in Amman in Jordan. In August 1996 it became the first Arab company to export pharmaceutical products to the United States. It was first listed on the London Stock Exchange in 2005. Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005 and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006. In 2007 the Company went on to buy APM in Jordan, Alkan Pharma in Egypt,APM and Al Jazeera Pharma in Saudi Arabia Thymoorgan in Germany and Ribosepharm in Germany. It also acquired Multi-Source Injectables in the USA in October 2010. In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).
AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with HikmaPharmaceuticalsUSA, Inc.
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with HikmaPharmaceuticalsUSA... today announced that it has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc.
The expiration of patents allows pharmaceutical companies to produce cost-effective alternatives, thereby increasing competition and reducing treatment expenses for patients ... Teva Pharmaceutical Industries Ltd ...HikmaPharmaceuticalsPLC Viatris Inc.
Hikma 2024 full year results - Q&A transcript (edited) ...Ladies and Gentlemen, welcome to the Hikma FY24 Results ... Hikma Pharmaceuticals plc published this content on February 28, 2025, and is solely responsible for the information contained therein.
AMMAN — HikmaPharmaceuticalsPLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion compared to $2.875 billion in 2023, according to audited figures released on Wednesday.
But HikmaPharmaceuticals was the biggest blue-chip faller, shedding 6.2 per cent, or 142p, to 2154p as the generic medicines firm saw its core operating profits and weaker margins disappoint, despite a jump in annual revenues ....
But HikmaPharmaceuticals was the biggest blue-chip faller, shedding 6.2 per cent, or 142p, to 2154p as the generic medicines firm saw its core operating profits and weaker margins disappoint, despite a jump in annual revenues. RELATED ARTICLES ... .
Hikma 2024 preliminary results presentation transcript ... to Hikma ... Hikma Pharmaceuticals plc published this content on February 26, 2025, and is solely responsible for the information contained therein.